ProCE Banner Activity

Economic Evaluation: Addition of Carfilzomib to Lenalidomide/Dexamethasone Cost Effective for R/R MM

Slideset Download
Conference Coverage
The current modeling analysis shows that the addition of carfilzomib to lenalidomide/dexamethasone provides an additional 1.99 LYs and 1.67 QALYs vs lenalidomide/dexamethasone, as well as providing an ICER that ranges between

Released: June 10, 2016

Expiration: June 09, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals